Press Releases

Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits and Facilitates More Than 100,000 Appointments in the First Month

Kyruus announced that it has expanded its patient access platform to enable customers to offer online consumer scheduling for COVID-19 vaccine visits. The vaccine scheduling capabilities are available within the company’s award-winning online scheduling solution. Almost 10 health systems have already activated vaccine scheduling with Kyruus, cumulatively booking more than 100,000 appointments in the first month alone. Kyruus enables healthcare organizations to offer intuitive online scheduling with its Kyruus ProviderMatch for Consumers solution for websites and mobile apps. Coupling rich, search engine-optimized profiles with a dynamic care...

Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician Workflows

Augmedix, a provider of remote medical documentation and live clinical support, is announcing a rollout of a tech-enabled medical documentation service powered by virtual scribes and created specifically for busy Emergency Department (ED) environments, Augmedix trains remotely located scribes in emergency medicine documentation to alleviate the administrative burden for clinicians, which is especially important today as these providers are on the front lines of the COVID crisis. The virtual scribes use proprietary Augmedix technology to ensure consistent, accurate documentation, which adds value and potential return on...

Accolade to Acquire 2nd.MD

Accolade, a company that provides personalized solutions that help people better understand, navigate, and use the healthcare system and their workplace benefits, has signed a definitive agreement to acquire Innovation Specialists, LLC (d/b/a 2nd.MD), a leading expert medical opinion and decision support company. Healthcare utilization is expected to rise significantly in 2021 due to the effects of the COVID-19 pandemic. With that in mind, the integration of 2nd.MD with Accolade’s health and benefit solutions and clinical service offerings will make the healthcare experience simpler for employees...

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease. Many MRD tests available today for solid tumors require tissue samples and development of patient-specific assays, which can result in potential delay in treatment decisions. GRAIL’s targeted methylation platform could enable a blood-based MRD detection assay for solid tumors...

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study conducted under a U.S. Food and Drug Administration Investigational Device Exemption application to evaluate the implementation of Galleri in clinical practice. PATHFINDER has completed its second planned independent Data and Safety Monitoring Board review. GRAIL expects to present initial results from PATHFINDER, and additional clinical validation from GRAIL’s foundational Circulating Cell-free...

McKesson Ventures Expands Portfolio Development Team and Invests in Market Research

McKesson Ventures has added Lizzie Lee as its newest team member. She joins the firm as senior director, leading its portfolio development and market research efforts. With a decade of healthcare experience, Lee is well-positioned to help McKesson Ventures’ portfolio companies scale by developing and facilitating collaboration amongst the portfolio company, McKesson’s business units, and its customers. Lee will also lead market research efforts to further develop McKesson Ventures’ thought leadership on relevant, emerging trends in the healthcare industry. “I’m passionate about connecting the innovation of novel...

Aspen RxHealth Raises $23M Series B Funding Round Led by Bessemer Venture Partners

Aspen RxHealth, developer of a first-of-its-kind clinical pharmacy model developed by pharmacists for pharmacists that delivers value for health plans and risk-bearing providers, today announced the closure of a $23 million Series B funding round led by Bessemer Venture Partners, with participation from other strategic investors including McKesson Ventures, Novartis, and Takeda Digital Ventures. Previous investors Humana and Flare Capital Partners also participated. The funding will help Aspen RxHealth capitalize on the demand for its highly diverse community of pharmacists and poise the company for successful...

McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care

McKesson Corporation today announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer. Building on McKesson’s long history in community oncology, Ontada combines its real-world data and research capabilities with a leading suite of technologies for oncology clinicians, including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool, as well as a connection to a national community oncology network to transform the fight against cancer. Ontada’s...

McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures, along with its significantly enhanced electronic patient reported outcome (ePRO) module. “McKesson Ventures is excited to invest in Clinical Ink, a market leader in clinical trial enablement technology,” said Dave Schulte, McKesson Ventures senior vice president and managing director. “Clinical Ink’s innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring.” Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and...

Michelle Snyder, Digital Health Veteran, Joins McKesson Ventures

McKesson Ventures has hired Michelle Snyder as its newest investment partner. Snyder, a mobile health pioneer, is known for her leadership and guidance in building Epocrates, one of the healthcare industry’s first successful mobile health companies. She brings more than 25 years of healthcare experience to the McKesson Ventures team and will support investments in healthcare technology and services companies. Snyder’s hire also expands the number of female partners at McKesson Ventures, underscoring the firm’s commitment to diversifying its leadership team. Prior to joining McKesson Ventures, Snyder...